AHRQ seeks comment on acid reflux
This article was originally published in The Gray Sheet
Executive Summary
Agency for Healthcare Research and Quality is updating its 2005 report on gastroesophageal reflux disease (GERD) and is taking comments through April 15 on three key questions. First, AHRQ will examine the comparative effectiveness evidence of medical, surgical and newer forms of treatments in improving objective (such as carcinoma) and subjective outcomes (such as quality of life impact). Second, AHRQ seeks evidence supporting whether certain treatments are more effective on patient subgroups. Finally, the agency will look at adverse effects from the various therapies and whether changes in follow-up could help mitigate negative outcomes. The 2005 report on GERD treatments, the first comparative effectiveness research review released by AHRQ, found insufficient clinical data on endoscopic therapies (1"The Gray Sheet" Dec, 19, 2005)
You may also be interested in...
Inaugural AHRQ Comparative Review Questions GERD Device Therapy Data
Clinical trial data on endoscopic treatments for gastroesophageal reflux disease, or GERD, is not up to par with the available research on pharmaceutical or surgical options, according to the Agency for Healthcare Research & Quality
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.